The size of the global CRISPR genome editing market is expected to attain a value of USD 15.84 billion by 2028, growing at a 29.50% CAGR during the forecast period from USD 1.08 billion in 2021.
The size of the global CRISPR genome editing market is expected to attain a value of USD 15.84 billion by 2028, growing at a 29.50% CAGR during the forecast period from USD 1.08 billion in 2021. This report discusses market research on the CRISPR genome editing market, its market growth factors, and its challenges. The report also talks about the opportunities available to stakeholders, researchers, and potential investors for the CRISPR genome editing market, discussing the recent changes due to the pandemic.
CRISPR gene editing is a molecular genetically engineered approach for altering the genomes of living organisms. It's built on a reduced form of the CRISPR-Cas9 antiviral defense mechanism found in bacteria. The approach is important in biotechnology and medicine because it enables genes to be altered in vivo with exceptional accuracy, at a low cost, and with simplicity. It can be employed in the development of novel medications, farm goods, and genetically engineered organisms, as well as for disease and pest management. It may also be used to treat heritable gene illnesses and also diseases that are caused by somatic mutations.
COVID-19 is a newly identified virus that causes a contagious sickness. The global burden of the COVID-19 pandemic has prompted major pharmaceutical and biotechnology businesses, as well as participants in the CRISPR genomic market, to engage in vaccine research and development. The increased need for vaccinations and possible antiviral options has pushed genome editing techniques to the front of the line.
In COVID-19 outbreaks, molecular biology technologies of gene editing procedures like CRISPR have proven to be more important than traditional diagnosis or therapy methods. These instruments functioned as next generational testing and therapy procedures, ranging from quick and efficient diagnosis to more focused viral detection and killing of infectious viruses. The pandemic proved to be beneficial to the global CRISPR genome editing market.
Governments in numerous nations throughout the world have made large expenditures in genomics in past years, which have aided in the discovery and research of innovative CRISPR genome editing technologies. Furthermore, the availability of funding support has allowed university and government organizations to conduct extensive genome engineering research. The quantity of CRISPR genomics research efforts has increased significantly as a result of major government funding in genomics. This, in turn, is likely to fuel the global CRISPR genome editing market's expansion throughout the forecast period.
Off-target consequences from CRISPR-Cas9 are a big problem. Because Cas9 causes double-stranded breaks can potentially lead to cancer tumor formation. Moreover, the high incidence of off-target activity mutations in locations besides the targeted on-target location is a major source of worry. CRISPR can, for example, target a tumor suppressor gene or stimulate a cancer-causing mutation. This unfavorable consequence has caused problems for several firms conducting clinical studies. Clinical studies have been halted, and regulatory officials are demanding further study to improve the method's safety thereby restraining the market growth.
CRISPR allows for desired agricultural features by transferring DNA from the crop's own naturally occurring genetic variants, rather than from alternative reproductively incompatible creatures. This removes the possibility of foreign DNA contamination in the resulting plant and final items. Because the CRISPR procedure does not incorporate foreign DNA into the genetic material, many scientific experts regard plant products to be non-GMO, and at least some plants generated using this technology are non-GMO. This expands its application in agriculture, offering the potential for the worldwide CRISPR genome editing market to expand.
Human genome editing, according to bioethicists and experts, should not be tried since it affects genes and has a mutant impact that may be passed down generations. The majority of stakeholders feel that ongoing public discourse and debate are necessary to allow the public to determine whether or not CRISPR genome editing must be permitted for human genes. Because of bioethical concerns, around 40 nations prohibited or outlawed CRISPR genome editing research in the last decade. This has hampered the worldwide CRISPR genome editing business by constraining further research and development.
|Historic Years||2016 - 2020|
|Forecast Years||2021 - 2028|
|Segments Covered||By Product Type, By Application, and By End Use|
|Forecast Units||Value (USD Billion), and Volume (Units)|
|Quantitative Units||Revenue in USD million/billion and CAGR from 2021 to 2028|
|Regions Covered||North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, and Rest of World|
|Countries Covered||U.S., Canada, Mexico, U.K., Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Argentina, GCC Countries, and South Africa, among others|
|Number of Companies Covered||10 companies with scope for including additional 15 companies upon request|
|Report Coverage||Market growth drivers, restraints, opportunities, Porter’s five forces analysis, PEST analysis, value chain analysis, regulatory landscape, market attractiveness analysis by segments and region, company market share analysis, and COVID-19 impact analysis.|
|Customization Scope||Avail customized purchase options to meet your exact research needs.|
CRISPR Genome Editing Market: Segmentation Analysis
The global market is segregated on the basis of end-user, application, and region. Academics & government institutes, biotechnology & pharmaceutical firms, contract research organizations, and others are the types of end-users. Biotechnology & pharmaceutical businesses accounted for the greatest proportion of the global CRISPR genome editing market by end-user in 2021. Infectious illnesses and cancer are becoming more common, which is fueling research efforts throughout the world. The need for genetic modification in biotechnology and pharmaceutical industries is likely to rise as a result of this.
The market categories depending on the application include cell line engineering, genetic engineering, diagnostic applications, drug discovery & development, and others. The bulk of the market was responsible for the application of CRISPR technology for cell line genetic alteration in stem cell treatment and gene therapy, and it is predicted to grow fast. The ability to use this technology to create new compounds that may be used to treat diseases like malignant tumors and contagious diseases is anticipated to boost its popularity in the coming years.
Due to significant investments made by pharmaceutical & biotech businesses, rise in per capita income, enhanced health systems, accessibility of therapies, and affordability of state-of-the-art testing facilities & organizations in the region, North America has the largest proportion of the CRISPR gene editing market. Apart from that, throughout the forecast period, Asia Pacific is expected to develop at the quickest CAGR in the global CRISPR genome editing market.
CRISPR Genome Editing Market: Competitive Landscape
The major companies that are into intense research in order to capture the widest variety of CRISPR genome editing applications and gain a dominant position in the market are -
Genome editing techniques refer to addition, deletion, or alteration of genomic DNA sequence at particular locations. CRISPR/Cas9 is a short form for clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated protein 9. CRISPR sequences are palindromic in nature which means that the nucleotide sequence is the same in both the directions. Originally, CRISPR is a bacterial defense system in which the bacteria retain snippets of DNA from viruses. These CRISPR arrays help identify and destroy closely related virus DNA from future attacks. Bacteria use Cas9 enzyme to cut foreign DNA from viruses and thus disables the viral infection.
Similar mechanism from bacterial defense system is used in the laboratory. RNA with short guide sequence is synthesized in the laboratory. This RNA is also capable of binding to the Cas9 enzyme. The guide sequence on RNA helps to identify and bind a specific sequence in the genomic DNA. Thus RNA binds to a targeted sequence in the genomic DNA which is then cut by the Cas9 enzyme at the targeted region. Cell’s own DNA repair machinery is used to edit the genome. The sequence of DNA is added, deleted or replaced with a sequence of interest. Currently, the CRISPR genomic editing tool is in its infancy and is used in cell and animal models.
Ethical concerns are raised in editing human genomic sequence. In human, genomic editing is limited to the somatic cell level. Editing of germline cells will lead to changes in gene sequences at the embryo level, which could be passed on to future generations. Genome editing at the germline level is illegal in many countries owing to ethical safety and concern. However, genome editing has huge potential in the management of various disorders such as hemophilia, cystic fibrosis, heart disease, sickle cell disease, cancer, human immunodeficiency virus (HIV) infection and mental illness. Owing to potential benefits of CRISPR gene editing technique in complex disorders, it has gained global interest in commercialization of CRISPR gene editing products and leading market players have received large investments and venture capitals for its development and commercialization.
Transcription activator-like effector nuclease (TALENS), meganucleases and zinc finger nucleases (ZFN) are traditional gene-editing technologies. However, design complexity, restrictions in multiple mutations and transfection inefficiencies are few of the drawbacks of these traditional gene-editing techniques. CRISPR technique, on the other hand, is comparatively more accurate, faster and efficient gene editing tool. Although the ethical concerns limit the use of CRISPR genome editing in human, further research and technological advancements would make its use possible in the diagnosis and treatment of complex disorders.
Novel drug discovery initiatives by pharmaceutical and biotech companies drive the market growth. Other factors contributing to the market growth are late pregnancies causing birth disorders, rising demand for synthetic genes, huge investments in research and development, technological advancements in the field of molecular biology. Nevertheless, ethical issues pertaining to misuse of genome editing is a major concern and may hamper the market growth. Inadequate awareness and availability of other gene editing tools can restrict the growth of global CRISPR genome editing market. Developing contract research organizations (CRO) market in developing nations like India act as an opportunity for CRISPR genome editing market.
The global CRISPR genome editing market has been segmented based on applications, end-user, and region. Various applications of CRISPR genome editing market are genome editing, genetic engineering, gene library, human stem cells, and others. Other segment includes applications in genetically modified crops and organisms, cell line engineering. Genome editing segment holds the maximum share of the application segment. End users for CRISPR Genome Editing market are biotechnology companies, pharmaceutical companies and other. Other end users included in the report are academic research centers, research institutes etc.
North America region will lead the market during the forecast period. Advanced technology and healthcare infrastructure, government fund, and continuous research and development will promote the growth of the market in this region. Second largest market during the forecast period will be Europe, whereas Asia Pacific region will grow at the fastest rate. Favorable government fund for research and development, increased investments in healthcare research by biotech and pharmaceutical companies are some of the factors propelling the growth of the CRISPR genome editing market in this region. Latin America market is anticipated to grow moderately during the forecast period. Noticeable growth is expected for the Middle East and Africa region in the years to come.
Some of the key players in CRISPR genome editing market include Editas Medicine, Horizon Discovery PLC., CRISPR Therapeutics AG, Genscript, Sangamo Biosciences, Inc., Caribou Biosciences, Inc., Lonza Group AG, Transposagen Biopharmaceuticals, Integrated DNA Technologies, New England Biolabs Inc, Origene Technologies Inc., Thermo Fisher Scientific, Sigma-Aldrich Precision Biosciences, Cellectis, Intellia Therapeutics, Inc., Novartis among others.
Recently the government has started to fund projects in CRISPR genome edition or engineering providing ample support for organizations to conduct research. Secondly its implementation in agricultural sector as well is helping the market grow.
As per Zion Market Research, the size of the global CRISPR Genome Editing market is expected to attain a value of USD 15.84 billion by 2028, growing at a rate of growth at the rate of 29.50% CAGR during the forecast period from USD 1.08 billion in 2021.
North America is expected to lead the global CRISPR Genome Editing market due to significant investments made by pharmaceutical and biotech businesses, rise in per capita income, enhanced health systems, accessibility of therapies, and affordability of state-of-the-art testing facilities and organizations in the region.
Insights from Zion Market Research list Thermo Fisher Scientific (US), Merck KGaA (Germany), GenScript (China), Sangamo Therapeutics (US), Lonza (Switzerland), CRISPR Therapeutics AG (Switzerland), and Precision Biosciences (US) as the major companies that are into intense research in order to capture the widest variety of CRISPR genome editing applications.